OPKO Health (NASDAQ:OPK) Shares Down 7.6%

OPKO Health, Inc. (NASDAQ:OPK - Get Free Report)'s share price dropped 7.6% on Wednesday . The stock traded as low as $1.25 and last traded at $1.28. 5,388,312 shares traded hands during trading, a decline of 63% from the average daily volume of 14,588,397 shares. The stock had previously closed at $1.38.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on OPK shares. Barrington Research restated an "outperform" rating and set a $1.50 price objective on shares of OPKO Health in a research note on Monday, April 1st. HC Wainwright reissued a "buy" rating and set a $3.00 price target on shares of OPKO Health in a research report on Wednesday, April 3rd. Piper Sandler reaffirmed an "overweight" rating and issued a $5.00 price target on shares of OPKO Health in a report on Monday, April 1st. Finally, StockNews.com downgraded shares of OPKO Health from a "hold" rating to a "sell" rating in a research report on Friday, March 1st.

OPKO Health Price Performance

The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.22 and a current ratio of 1.55. The company's fifty day moving average price is $1.04 and its 200 day moving average price is $1.25. The firm has a market capitalization of $885.18 million, a price-to-earnings ratio of -5.08 and a beta of 1.82.

OPKO Health (NASDAQ:OPK - Get Free Report) last announced its quarterly earnings results on Tuesday, February 27th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.09). The business had revenue of $181.90 million for the quarter, compared to the consensus estimate of $177.53 million. OPKO Health had a negative return on equity of 12.69% and a negative net margin of 21.76%. The business's revenue was down 1.9% on a year-over-year basis. During the same quarter last year, the business posted ($0.11) EPS. Equities research analysts expect that OPKO Health, Inc. will post -0.33 earnings per share for the current year.

Insider Buying and Selling at OPKO Health

In other OPKO Health news, Vice Chairman Jane Ph D. Hsiao bought 150,000 shares of the business's stock in a transaction on Wednesday, January 17th. The shares were purchased at an average price of $0.95 per share, with a total value of $142,500.00. Following the purchase, the insider now directly owns 27,999,880 shares of the company's stock, valued at $26,599,886. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, CEO Phillip Md Et Al Frost bought 511,531 shares of the company's stock in a transaction that occurred on Thursday, January 11th. The shares were purchased at an average price of $0.94 per share, with a total value of $480,839.14. Following the completion of the acquisition, the chief executive officer now directly owns 203,968,225 shares in the company, valued at $191,730,131.50. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Vice Chairman Jane Ph D. Hsiao purchased 150,000 shares of the stock in a transaction dated Wednesday, January 17th. The shares were purchased at an average price of $0.95 per share, for a total transaction of $142,500.00. Following the completion of the transaction, the insider now owns 27,999,880 shares in the company, valued at approximately $26,599,886. The disclosure for this purchase can be found here. Over the last 90 days, insiders have bought 6,691,531 shares of company stock worth $6,384,039. 47.26% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of OPK. Invesco Ltd. boosted its stake in OPKO Health by 300.4% in the 3rd quarter. Invesco Ltd. now owns 5,164,180 shares of the biotechnology company's stock worth $8,263,000 after purchasing an additional 3,874,519 shares during the period. SG Americas Securities LLC boosted its position in shares of OPKO Health by 19.3% in the fourth quarter. SG Americas Securities LLC now owns 244,294 shares of the biotechnology company's stock worth $369,000 after buying an additional 39,459 shares during the period. EP Wealth Advisors LLC grew its holdings in shares of OPKO Health by 140.3% during the third quarter. EP Wealth Advisors LLC now owns 30,900 shares of the biotechnology company's stock valued at $49,000 after buying an additional 18,041 shares in the last quarter. Charles Schwab Investment Management Inc. raised its position in OPKO Health by 7.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 5,549,946 shares of the biotechnology company's stock valued at $8,880,000 after buying an additional 405,106 shares during the period. Finally, Barclays PLC lifted its stake in OPKO Health by 17.4% in the 3rd quarter. Barclays PLC now owns 188,421 shares of the biotechnology company's stock worth $302,000 after acquiring an additional 27,946 shares in the last quarter. Institutional investors own 64.63% of the company's stock.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.